CBU
LAB icon

CIBC Bancorp USA’s Standard BioTools LAB Stock Holding History

CIBC Bancorp USA’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,877
Closed -$14.6K – 1994
2026
Q1 		$14.6K Buy
+15,877
New +$19.2K ﹤0.01% 1746
2025
Q3 		$41.5K Buy
+31,908
New +$41.8K ﹤0.01% 1429

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's LAB Position: Q2 2026 in Review

CIBC Bancorp USA sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 15,877 shares — an estimated $14.6K sold.

CIBC Bancorp USA first reported a position in LAB in Q3 2025 and held it in 2 quarters. The position peaked at $41.5K in Q3 2025. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • CIBC Bancorp USA reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • CIBC Bancorp USA sold 15,877 Standard BioTools shares in Q2 2026, an estimated $14.6K.
  • CIBC Bancorp USA first reported a position in Standard BioTools in Q3 2025 and held it in 2 quarters.
  • CIBC Bancorp USA's Standard BioTools position peaked at $41.5K in Q3 2025.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.